Boiron SA (BOI) - Total Assets

Latest as of December 2025: €602.81 Million EUR ≈ $704.75 Million USD

Based on the latest financial reports, Boiron SA (BOI) holds total assets worth €602.81 Million EUR (≈ $704.75 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Boiron SA (BOI) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Boiron SA - Total Assets Trend (2001–2025)

This chart illustrates how Boiron SA's total assets have evolved over time, based on quarterly financial data. See Boiron SA book value and equity for net asset value and shareholders' equity analysis.

Boiron SA - Asset Composition Analysis

Current Asset Composition (December 2025)

Boiron SA's total assets of €602.81 Million consist of 48.7% current assets and 51.3% non-current assets.

Asset Category Amount (EUR) % of Total Assets
Cash & Equivalents €0.00 13.2%
Accounts Receivable €104.92 Million 17.4%
Inventory €98.60 Million 16.4%
Property, Plant & Equipment €0.00 0.0%
Intangible Assets €30.28 Million 5.0%
Goodwill €89.60 Million 14.9%

Asset Composition Trend (2001–2025)

This chart illustrates how Boiron SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Boiron SA market cap and net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Boiron SA's current assets represent 48.7% of total assets in 2025, a decrease from 57.7% in 2001.
  • Cash Position: Cash and equivalents constituted 13.2% of total assets in 2025, up from 9.5% in 2001.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 7.0% in 2001.
  • Asset Diversification: The largest asset category is accounts receivable at 17.4% of total assets.

Boiron SA Competitors by Total Assets

Key competitors of Boiron SA based on total assets are shown below.

Company Country Total Assets
Takeda Pharmaceutical Company Limited
F:TKDA
Germany €15.41 Trillion
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
China CN¥19.57 Billion
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
China CN¥2.30 Billion
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
China CN¥8.59 Billion
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
China CN¥925.41 Million
Jw Pharmac
KO:001060
Korea ₩605.27 Billion
Kamada
TA:KMDA
Israel ILA377.21 Million
Samjin Pharm
KO:005500
Korea ₩449.14 Billion

Boiron SA - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.22 2.51 2.50
Quick Ratio 1.48 1.61 2.02
Cash Ratio 0.00 0.00 0.00
Working Capital €161.44 Million €169.17 Million €264.91 Million

Boiron SA - Advanced Valuation Insights

This section examines the relationship between Boiron SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.22
Latest Market Cap to Assets Ratio 0.79
Asset Growth Rate (YoY) 4.6%
Total Assets €602.81 Million
Market Capitalization $477.46 Million USD

Valuation Analysis

Below Book Valuation: The market values Boiron SA's assets below their book value (0.79x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Boiron SA's assets grew by 4.6% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Boiron SA (2001–2025)

The table below shows the annual total assets of Boiron SA from 2001 to 2025.

Year Total Assets Change
2025-12-31 €602.81 Million
≈ $704.75 Million
+4.59%
2024-12-31 €576.33 Million
≈ $673.79 Million
-2.35%
2023-12-31 €590.20 Million
≈ $690.01 Million
-25.24%
2022-12-31 €789.49 Million
≈ $923.00 Million
+2.44%
2021-12-31 €770.70 Million
≈ $901.03 Million
-1.42%
2020-12-31 €781.82 Million
≈ $914.03 Million
+2.29%
2019-12-31 €764.28 Million
≈ $893.53 Million
-0.36%
2018-12-31 €767.08 Million
≈ $896.79 Million
-4.16%
2017-12-31 €800.40 Million
≈ $935.76 Million
+6.01%
2016-12-31 €755.03 Million
≈ $882.71 Million
+8.57%
2015-12-31 €695.45 Million
≈ $813.05 Million
+3.87%
2014-12-31 €669.55 Million
≈ $782.77 Million
+0.29%
2013-12-31 €667.59 Million
≈ $780.48 Million
+15.24%
2012-12-31 €579.28 Million
≈ $677.24 Million
-1.42%
2011-12-31 €587.61 Million
≈ $686.97 Million
+5.24%
2010-12-31 €558.34 Million
≈ $652.76 Million
+6.98%
2009-12-31 €521.93 Million
≈ $610.20 Million
+12.65%
2008-12-31 €463.34 Million
≈ $541.70 Million
+8.16%
2007-12-31 €428.39 Million
≈ $500.83 Million
+3.96%
2006-12-31 €412.06 Million
≈ $481.74 Million
-3.56%
2005-12-31 €427.25 Million
≈ $499.50 Million
+57.65%
2004-12-31 €271.02 Million
≈ $316.85 Million
+9.29%
2003-12-31 €247.97 Million
≈ $289.91 Million
+7.47%
2002-12-31 €230.73 Million
≈ $269.74 Million
+12.08%
2001-12-31 €205.86 Million
≈ $240.67 Million
--

About Boiron SA

PA:BOI France Drug Manufacturers - Specialty & Generic
Market Cap
$564.29 Million
€482.67 Million EUR
Market Cap Rank
#12322 Global
#192 in France
Share Price
€27.80
Change (1 day)
+1.46%
52-Week Range
€20.90 - €31.70
All Time High
€59.48
About

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics, and CBD-based products. It also provides homeopathic specialties compr… Read more